The Burden of the Serious and Difficult-to-Treat Infections and a New Antibiotic Available: Cefiderocol.
Front Pharmacol
; 11: 578823, 2020.
Article
em En
| MEDLINE
| ID: mdl-33628170
ABSTRACT
Background:
Infection is a disease that can occur due to the entrance of a virus, bacteria, and other infectious agents. Cefiderocol is innovative cephalosporin drug that belongs to a special class of antibiotics, sideromycins, which are taken up by bacterial cells through active transport. The unique cell entry and stability to ß-lactamases allow cefiderocol to overcome the most common resistance mechanisms in Gram-negative bacteria.Objective:
This article aims to highlight the therapeutic efficacy, safety and tolerability of cefiderocol, with a focus on the FDA label.Methods:
The pharmacological properties of cefiderocol are also summarized. In this review, we conducted literature research on the PubMed database using the following keywords "antimicrobial treatment", "new antibiotic", "cefiderocol", "siderophore cephalosporin"; "multidrug-resistant", "Gram-negative bacilli", "critically ill patients"; "severe bacterial infections".Results:
There were identified the most relevant data about the pathophysiology of serious bacterial infections, antibacterial mechanism of action, microbiology, mechanisms of resistance, pharmacokinetic and pharmacodynamic properties of cefiderocol.Conclusion:
The results highlighted there appeared to be clinical benefit from cefiderocol in the treatment of infections caused by Gram-negative aerobic microorganisms in adult patients with severe infections and limited treatment options.
Texto completo:
1
Bases de dados:
MEDLINE
Idioma:
En
Revista:
Front Pharmacol
Ano de publicação:
2020
Tipo de documento:
Article
País de afiliação:
Irã